Alan Carr, Ph.D.
Senior Analyst, CNS/Metabolic Disorders, Inflammatory & Infectious Disease

Telephone: (212) 705-0435
Email: acarr@needhamco.com

Alan Carr joined Needham & Company in 2006. From 2001 to 2006 Alan worked in Yale’s technology transfer group, the Office of Cooperative Research, where he out-licensed a number of technologies and therapeutic product candidates developed in Yale labs and helped establish start-up companies in the New Haven area. Prior to that he was at J. Bush & Co., a New Haven investment firm, where he covered companies in the research tool and healthcare space. His post-doctoral work was centered on the regulation of neuronal development during embryogenesis. He earned his undergraduate degree at Albion College and earned his Ph.D. in Molecular Biophysics and Biochemistry from Yale University.

Dalton L. Chandler
Senior Analyst, Medical Technology

Telephone: (212) 705-0315
Email: dchandler@needhamco.com

Dalton Chandler joined Needham & Company in 1998. Prior to Needham, Dalton was with H.C. Wainwright & Co., where he was primarily focused on covering healthcare information technology companies. His background includes experience in corporate finance and mergers & acquisitions in the media, as well as the advertising and healthcare industries. He holds a BS degree in Electrical Engineering from the University of Kentucky and an MBA in Finance from Indiana University.

Sameer Harish
Senior Analyst, Medical Devices & Diagnostics

Telephone: (415) 262-4897
Email: sharish@needhamco.com

Sameer Harish joined Needham & Company in 2005. Prior to joining Needham, Sameer spent three years on the buy side at Symmetry Capital covering health care companies with a focus on medical devices and diagnostics. His industry experience includes research and development work at Guidant and Incyte Genomics. He received a BA from the University of California at Berkeley, where he studied Molecular and Cell Biology.

Mark Monane, M.D., M.S.
Senior Analyst, Biotechnology & Life Sciences

Telephone: (212) 705-0346
Email: mmonane@needhamco.com

Dr. Mark Monane joined Needham & Company in 2000. He currently serves as Needham’s Senior Analyst in biotechnology and biopharmaceuticals covering small and mid-cap stocks in the therapeutics areas of cardiovascular medicine, oncology, CNS/metabolic diseases, and infectious/inflammatory disorders. Dr. Mark's research on medication use and geriatrics has resulted in more than 50 original articles and review publications in journals such as Archives of Internal Medicine, Journal of the American Medical Association, Journal of the American Geriatrics Society, Hypertension and Clinical Pharmacology and Therapeutics. He served as an Assistant Professor of Medicine at Harvard Medical School until he joined Merck-Medco Managed Care as Senior Director of Geriatrics in 1996. He is also an Adjunct Associate Clinical Professor at Rutgers School of Pharmacy in New Jersey. Mark is board certified in internal medicine, geriatric medicine, clinical pharmacology, utilization review/quality assurance, and healthcare management. He holds an AB degree from Columbia University, an MD from New York University School of Medicine, an MS degree from Harvard School of Public Health, and an MBA from Columbia Business School. He completed postdoctoral training in primary care internal medicine at Montefiore Hospital, geriatric medicine at Harvard Medical School, and geriatric clinical pharmacology at Harvard Medical School.

Elliot Wilbur, CFA
Senior Analyst, Specialty Pharmaceuticals

Telephone: (212) 705-0333
Email: ewilbur@needhamco.com

Elliot Wilbur joined Needham & Company in 2008. Elliott covers the drug delivery, specialty, and generic pharmaceutical sectors for Needham & Company, LLC focusing on small-to-mid-size emerging pharmaceutical franchises. Prior to joining Needham, he was a senior equity research analyst covering the specialty pharmaceutical sector for CIBC World Markets, a position he had held since 2001. Before joining CIBC’s healthcare research team, he spent three years working for the firm's equity portfolio strategy group designing proprietary multi-factor stock selection models for use in sector and industry weighting determinations. Prior to CIBC, he was a research associate with William O'Neil & Co. focusing on fundamental and technical analysis of U.S. equities. Elliot has twice been recognized for his stock selection skill in The Wall Street Journal’s All-Star Analyst survey, and has consistently maintained one of the broadest universes among specialty pharmaceutical analysts on Wall Street. He is a summa cum laude graduate of Robert Morris College, where he received a BS in Finance and a minor in Quantitative Analysis and earned an MBA in Finance from the Anderson School of Business at UCLA.